Sydney-based investment firm Factory Capital has announced a significant A$25 million commitment to establish women's midlife health as a formal institutional investment category. This initiative begins with the launch of the Institute Advancing Women's Health (InAWH), an Austin-based nonprofit, which will pioneer the development of clinical infrastructure. The firm's strategy aims to build a solid foundation of treatment protocols and clinician training before deploying capital into commercial ventures.
An Unconventional Infrastructure-First Strategy
Factory Capital is adopting a structurally unusual approach by prioritizing the development of foundational healthcare systems over direct startup investments. Unlike most venture capitalists who fund individual companies and hope the ecosystem matures around them, this strategy focuses on building the essential plumbing first. By creating standardized care pathways and training, the firm intends to de-risk future investments and foster a more scalable market environment.
The firm believes this foundational work is necessary to attract larger pools of institutional capital into the sector. According to its analysis, the primary barrier to investment has not been a lack of founders but the severe fragmentation across clinical, payer, and consumer channels. This fragmentation makes it difficult for limited partners to underwrite a thematic fund, a problem Factory Capital aims to solve directly.
Experienced Leadership to Steer the Initiative
The initiative is spearheaded by partner and managing director Anna Samuelsson, whose personal experience navigating perimenopausal symptoms informed the strategy's direction. She was motivated by the challenges she faced in receiving appropriate care, which highlighted a critical gap in the healthcare system. Samuelsson's vision is to transform this underserved area into a robust and investable category that improves health outcomes for women.
To lead the newly formed InAWH, Factory Capital has appointed Paula Schneider as Chief Executive Officer. Schneider brings a wealth of leadership experience from her previous roles as CEO of the Susan G. Komen Foundation and American Apparel. Her extensive background in both nonprofit and corporate sectors positions her to effectively guide the institute's mission of advancing women's health.
Targeted Investments and a Clear Focus
The A$25 million fund will be deployed across a concentrated portfolio of five to ten companies, indicating a hands-on investment approach. With implied check sizes ranging from A$2.5 million to A$5 million, the firm will provide substantial support to its selected ventures. This focused strategy allows for deeper engagement and alignment with the companies building upon the new clinical infrastructure.
Factory Capital has clearly defined its investment thesis, targeting businesses in telehealth-led menopause care, employer benefits platforms, and clinical-grade supply chains. The firm will specifically avoid pure direct-to-consumer supplement brands that lack a clinical component, as well as fertility-focused businesses. This disciplined focus ensures that all investments directly contribute to building a cohesive and clinically sound midlife health ecosystem.
A Patient and Strategic Capital Model
This initiative is not structured as a conventional venture vehicle funded by limited partners, which sets it apart from typical market approaches. Instead, Factory Capital is funding the platform from its own balance sheet, affording it greater strategic patience. This model allows for a longer timeline to achieve commercial traction, which is essential for building a new market category from the ground up.
The women's health initiative is part of Factory Capital's broader HEAL platform, which concentrates on early-to-mid-stage investments across health, education, and adjacent sectors. This context underscores the firm's commitment to fostering long-term, impactful growth in foundational industries. The new platform aligns perfectly with its overarching mission to support sectors vital to societal well-being and advancement.
Factory Capital's A$25 million commitment represents a pioneering effort to legitimize and structure the women's midlife health market for institutional investment. By building the clinical framework before deploying growth capital, the firm is addressing systemic fragmentation and creating a more viable path for innovation. This patient, infrastructure-first approach could unlock a global market estimated to be worth hundreds of billions and fundamentally improve healthcare for women.